In Hong Kong, multiple authorities are responsible for the oversight and regulation of cellular therapy products. The Department of Health serves as the principle advising authority to the government of Hong Kong for developing and executing public health laws and statuatory functions. Additionally, Hong Kong’s Drug Office has the authority to regulate pharmaceutical products including biological products from human origin. At the time of this writing, specific laws, regulations, and guidelines could not be found on the websites belonging to the Department of Health or the Hong Kong Drug Office.
(October 2014)
AABB to Present New CGT Standards at Meeting on the Mesa
September 16, 2025
AABB Celebrates Apheresis Awareness Day, Releases New Apheresis Publication
September 16, 2025
FDA to Host Virtual Town Hall on Gene Therapy Manufacturing
September 11, 2025